Loading the records…
Loading the records…
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Chin Richard, holds the title of Director at Cytek Biosciences, Inc..
On 2026-11-18, the insider transacted 6,107 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Chin Richard (Director) exercised options for $0 of $CTKB
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.